Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
7(100.0%)
7Total
Phase 1(7)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT02535533Phase 1Completed

SLM + Axitinib for Clear Cell RCC

Role: lead

NCT07404332Phase 1Not Yet Recruiting

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

Role: lead

NCT05363631Phase 1Active Not Recruiting

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Role: lead

NCT03173976Phase 1Active Not Recruiting

Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

Role: lead

NCT05190315Phase 1Completed

Chlorpromazine and Standard of Care in Glioblastoma

Role: lead

NCT03508726Phase 1Completed

High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

Role: lead

NCT02959164Phase 1Completed

Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Role: lead

All 7 trials loaded